20 completed, 4 recruiting, 4 terminated, 3 active not recruiting. 33 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 33 | Completed 20, Recruiting 4, Terminated 4, Active not recruiting 3, Unknown 1, Withdrawn 1 |
| Phase 2 | 8 | Completed 6, Terminated 1, Unknown 1 |
Follow Eczema: new trials by email Literature Review of Eczema trials Research Report on Eczema
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic Dermatitis DCY636, Placebo - Dermatitis, Atopic | Phase 1 | Recruiting | Novartis Pharmaceuticals | 63 | 2026-06-02 | 2026-08-19 |
| First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis REGN20423, Placebo - Healthy Volunteer, Atopic Dermatitis | Phase 1 | Recruiting | Regeneron Pharmaceuticals | 144 | 2026-05-22 | 2026-10-07 |
| Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234 ARQ-234, Placebo - Atopic Dermatitis (AD), Eczema | Phase 1 | Recruiting | Arcutis Biotherapeutics, Inc. | 125 | 2026-03-02 | 2026-10-23 |
| The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis Onabotulinum Toxin Type A - Phase 1b, Onabotulinum Toxin Type A - Phase 2 - Atopic Dermatitis (AD) | Phase 1 | Active not recruiting | Daniel Kaplan | 8 | 2025-07-17 | 2026-10-06 |
| Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) ShA9 Topical Gel, Hydrocortisone Ointment, Clobetasol Ointment - Atopic Dermatitis | Phase 1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 86 | 2025-05-22 | 2026-07-02 |
| Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus ATTO-1310, ATTO-1310 Placebo - Normal Volunteers, Atopic Dermatitis (AD) | Phase 1 | Completed | Attovia Therapeutics Inc | 108 | 2025-01-14 | 2026-09-11 |
| Topical ENS-002 for Atopic Dermatitis in Adults ENS-002 - Atopic Dermatitis, Atopic Dermatitis Eczema | Phase 1 | Terminated | Concerto Biosciences | 9 | 2024-09-18 | 2025-08-14 |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Participants With Atopic Dermatitis BMS-986326, Placebo - Dermatitis, Atopic | Phase 1 | Completed | Bristol-Myers Squibb | 64 | 2024-03-06 | 2025-12-08 |
| A Study to Evaluate Rocatinlimab (AMG 451) in Healthy Chinese Participants Rocatinlimab - Atopic Dermatitis | Phase 1 | Completed | Amgen | 20 | 2024-01-23 | 2026-01-07 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD) Placebo, IMG-007 - Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis | Phase 1 / Phase 2 | Terminated | Inmagene LLC | 13 | 2023-08-09 | 2025-11-06 |
| Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis XmAb27564, Placebo - Psoriasis, Atopic Dermatitis | Phase 1 | Terminated | Xencor, Inc. | 23 | 2022-10-10 | 2025-12-02 |
| Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1% Fexofenadine Hydrochloride Topical Lotion 1% (OP2101) - Atopic Dermatitis, Atopic Dermatitis Eczema | Phase 1 | Completed | OrchestratePharma GmbH | 12 | 2022-04-01 | 2023-03-29 |
| Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema ARQ-151 cream 0.15%, ARQ-151 cream 0.05% - Atopic Dermatitis (Eczema) | Phase 1 | Completed | Arcutis Biotherapeutics, Inc. | 101 | 2019-12-23 | 2023-07-24 |
| A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants PF-07038124 and Vehicle, PF-07038124 or vehicle - Dermatitis Atopic | Phase 1 | Completed | Pfizer | 34 | 2019-10-29 | 2020-05-14 |
| Safety and Efficacy of a Topical Scalp Treatment for Dry Scalp Conditions in Children and Adult Natural Treatment - Dermatitis, Seborrheic, Dry Skin; Eczema | Phase 1 / Phase 2 | Completed | Ann & Robert H Lurie Children's Hospital of Chicago | 77 | 2019-07-08 | 2025-02-24 |
| A Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects With Atopic Dermatitis Experimental: B244 - Eczema, Atopic Dermatitis | Phase 1 | Completed | AOBiome LLC | 28 | 2018-12-07 | 2024-08-05 |
| A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis ASN002, Placebo Oral Tablet - Dermatitis, Atopic, Dermatitis Eczema | Phase 1 | Completed | Asana BioSciences | 36 | 2017-04-12 | 2023-05-10 |
| A Study to Evaluate the Efficacy and Safety of HAT01H in Atopic Dermatitis HAT01H Cream, Vehicle Cream - Atopic Dermatitis, Eczema | Phase 1 / Phase 2 | Completed | Haus Bioceuticals | 30 | 2017-03-26 | 2018-11-07 |
| Examination of Whether Host Preconditioning Modifies Short-term Transplant Survival Pre-Treatment with Dial liquid antibacterial soap, Control - Atopic Dermatitis, Eczema | Phase 1 | Withdrawn | University of California, San Diego | 2016-06-01 | 2020-11-05 | |
| A 47 Hour Occlusive Cutaneous Skin Patch Test on Adult Subjects With Dry/Atopic Skin Eczema Repair Emollient - Eczema | Phase 1 | Completed | Reckitt Benckiser Healthcare (UK) Limited | 33 | 2016-04-01 | 2016-06-03 |
Showing 20 of 33. Sign in to see all of them.
Dermatitis, Atopic (26) · Dermatitis (5) · Asthma (2) · Hypersensitivity (2) · Pruritus (2) · Psoriasis (2) · Skin Diseases (2) · Chronic Urticaria (1) · Dermatitis, Allergic Contact (1) · Dermatitis, Contact (1) · Dermatitis, Seborrheic (1) · Exanthema (1) · Immune System Diseases (1) · Infections (1)
Skin and Connective Tissue Diseases (33) · Skin Diseases, Eczematous (32) · Skin Diseases (31) · Dermatitis (28) · Hypersensitivity, Immediate (28) · Immune System Diseases (28) · Hypersensitivity (27) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (26) · Genetic Diseases, Inborn (26) · Skin Diseases, Genetic (25) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Skin Diseases, Papulosquamous (3) · Bronchial Diseases (2) · Lung Diseases (2)
Caffeine (1) · Clobetasol (1) · Fatty Acids, Omega-3 (1) · Gels (1) · Interleukin 1 Receptor Antagonist Protein (1) · Metoprolol (1) · Midazolam (1) · NF-kappaB decoy (1) · Olive Oil (1) · Omeprazole (1) · Steroids (1) · Tacrolimus (1) · Warfarin (1) · betamethasone-17,21-dipropionate (1) · difamilast (1)
Arcutis Biotherapeutics, Inc. (2) · Copenhagen Studies on Asthma in Childhood (2) · Haus Bioceuticals (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Novartis Pharmaceuticals (2) · Regeneron Pharmaceuticals (2) · AOBiome LLC (1) · Amgen (1) · Anesiva, Inc. (1) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · Asana BioSciences (1) · Attovia Therapeutics Inc (1) · Bristol-Myers Squibb (1) · Concerto Biosciences (1) · Daniel Kaplan (1)
United States (20) · Canada (6) · Denmark (2) · Germany (2) · Israel (2) · Bangladesh (1) · Belgium (1) · China (1) · Czechia (1) · France (1) · Hong Kong (1) · India (1) · Japan (1) · Netherlands (1) · Poland (1)
David Berk, MD (2) · Andria Langenberg, MD (1) · Bernardo Cervantes, PhD (1) · Christy Harutunian (1) · Daniel Kaplan, MD, PhD (1) · David Zammit, Ph.D. (1) · Donald Leung, MD, PhD (1) · Emma Guttmann, MD (1) · Eric Sicard, MD (1) · Joshua D Milner, M.D. (1) · Judith Ng-Cashin, MD (1)
PMID 36184023, PMID 17346444, PMID 26813208, PMID 28029926, PMID 29077711, PMID 29498038, PMID 29567358, PMID 30181143, PMID 30418579, PMID 31381020, PMID 32091548, PMID 33289844, PMID 33653805, PMID 34927195, PMID 35105560, PMID 37380711, PMID 37696621, PMID 38072183, PMID 38569788, PMID 39077939, PMID 39196551, PMID 40865727, PMID 41771441, PMID 42149595, PMID 42463642
2008 (1), 2025 (1)